IRIS
MERLINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.940
AS - Asia 13.732
EU - Europa 9.849
SA - Sud America 1.718
AF - Africa 489
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 17
AN - Antartide 1
Totale 43.775
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.533
CN - Cina 6.303
SG - Singapore 3.233
IE - Irlanda 2.557
HK - Hong Kong 1.497
BR - Brasile 1.267
VN - Vietnam 1.249
RU - Federazione Russa 1.155
FI - Finlandia 1.106
UA - Ucraina 1.078
DE - Germania 1.048
IT - Italia 714
FR - Francia 668
SE - Svezia 489
GB - Regno Unito 477
IN - India 330
ZA - Sudafrica 282
CA - Canada 202
BD - Bangladesh 201
AR - Argentina 154
JP - Giappone 126
MX - Messico 123
IQ - Iraq 112
TR - Turchia 95
PL - Polonia 82
PK - Pakistan 77
NL - Olanda 75
BE - Belgio 72
CO - Colombia 69
VE - Venezuela 63
ES - Italia 60
ID - Indonesia 59
EC - Ecuador 54
AT - Austria 52
SA - Arabia Saudita 47
UZ - Uzbekistan 44
MA - Marocco 43
PH - Filippine 43
CL - Cile 32
KE - Kenya 32
LT - Lituania 31
CZ - Repubblica Ceca 30
IR - Iran 29
PY - Paraguay 29
AE - Emirati Arabi Uniti 26
JO - Giordania 26
IL - Israele 25
MY - Malesia 25
TN - Tunisia 22
AU - Australia 21
JM - Giamaica 20
KZ - Kazakistan 19
AL - Albania 18
EG - Egitto 18
GR - Grecia 18
ET - Etiopia 17
MU - Mauritius 17
NP - Nepal 17
BO - Bolivia 16
DZ - Algeria 16
UY - Uruguay 16
PE - Perù 15
AZ - Azerbaigian 14
KG - Kirghizistan 14
KR - Corea 14
LB - Libano 13
PT - Portogallo 13
LV - Lettonia 12
RO - Romania 12
TH - Thailandia 12
DK - Danimarca 11
BG - Bulgaria 10
EU - Europa 10
HU - Ungheria 10
NI - Nicaragua 10
PA - Panama 10
PS - Palestinian Territory 9
HR - Croazia 8
OM - Oman 8
SY - Repubblica araba siriana 8
AM - Armenia 7
CH - Svizzera 7
CR - Costa Rica 7
NZ - Nuova Zelanda 7
BB - Barbados 6
CY - Cipro 6
DO - Repubblica Dominicana 6
EE - Estonia 6
LK - Sri Lanka 6
NG - Nigeria 6
SN - Senegal 6
BH - Bahrain 5
GA - Gabon 5
HN - Honduras 5
MD - Moldavia 5
RS - Serbia 5
AO - Angola 4
BN - Brunei Darussalam 4
GE - Georgia 4
MM - Myanmar 4
Totale 43.683
Salva come PNG Salva come JPEG
Città #
Dublin 2.549
Chandler 2.425
San Jose 1.946
Ashburn 1.631
Singapore 1.599
Jacksonville 1.524
Hong Kong 1.461
Nanjing 1.319
Dallas 1.238
Beijing 1.024
Boardman 811
Nanchang 564
Princeton 522
Lawrence 488
Lauterbourg 471
Wilmington 471
Ho Chi Minh City 427
Los Angeles 413
Shenyang 403
Medford 397
Hebei 380
Helsinki 349
Changsha 343
Hanoi 312
Jiaxing 304
Ann Arbor 276
New York 251
Tianjin 248
Johannesburg 235
Hangzhou 223
Buffalo 216
Redondo Beach 191
Moscow 190
Munich 180
Shanghai 162
Council Bluffs 151
Milan 137
Pavia 126
São Paulo 124
Santa Clara 118
Woodbridge 111
Tokyo 107
Orem 103
Norwalk 100
Chicago 80
Da Nang 79
Frankfurt am Main 77
Turku 74
Toronto 71
Piscataway 69
Brussels 68
Warsaw 68
Chennai 64
Verona 61
Fairfield 60
London 60
Montreal 60
Brooklyn 59
Seattle 58
Guangzhou 53
Denver 52
Des Moines 49
Atlanta 48
Stockholm 48
The Dalles 48
Zhengzhou 48
Baghdad 47
Nuremberg 46
Ningbo 44
Rio de Janeiro 43
Washington 43
Haiphong 42
Falkenstein 41
Houston 41
San Francisco 41
Mexico City 40
Amsterdam 37
Tashkent 37
Manchester 36
Pune 36
Phoenix 33
Boston 32
Hải Dương 30
Jinan 30
Ankara 28
Belo Horizonte 27
Biên Hòa 27
Kunming 27
Nairobi 27
Poplar 27
Brasília 25
Charlotte 25
Curitiba 25
Dhaka 25
Mumbai 24
Rome 24
Vienna 24
Lahore 22
Amman 21
Bologna 20
Totale 29.071
Salva come PNG Salva come JPEG
Nome #
Susceptibility to AA amyloidosis in rheumatic diseases: A critical overview. 210
A modified high-dose dexamethasone regimen for primary systemic amyloidosis 162
A novel method for proteomic analysis of immunoglobulin light chains and attribution to a germline gene-based family 162
Fibrillazione atriale e amiloidosi cardiaca AL: un connubio intrigante 158
A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis 152
Valore prognostico della presenza di bassi voltaggi elettrocardiografici nei pazienti affetti da amiloidosi AL 150
Liver biopsy discloses a new apolipoprotein AI hereditary amyloidosis in several unrelated Italian families 148
Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study 144
A novel AbetaPP mutation exclusively associated with cerebral amyloid angiopathy. 139
Amyloid fibrils derived from the apolipoprotein A1 Leu174Ser variant contain elements of ordered helical structure. 139
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis. 138
Functional correlates of N-terminal natriuretic peptide type B (NT-proBNP) response to therapy in cardiac light chain (AL) amyloidosis 136
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 136
Advantages of the lognormal approach to determining reference change values for N-terminal propeptide B-type natriuretic peptide 134
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 133
Amyloid typing: immunoelectron microscopy 133
Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils:inhibition of amyloidogenesis. 133
AMICA: an electronic patient record specifically designed for an amyloidosis network 133
A Strategy for Synthesis of Pathogenic Human Immunoglobulin Free Light Chains in E-coli 132
Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. 131
Abnormalities in thrombin-antithrombin pathway in primary systemic amyloidosis. 131
Beta2-microglobulin isoforms display an heterogeneous affinity for type I collagen. 130
Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis 130
Heavy chain disease can be detected by capillary zone electrophoresis. 129
Amyloidogenic light chains induce human cardiac fibroblast toxicity through alteration of mitochondrial functionality 129
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 129
Characterization of immunoglobulin variable regions of two human pathogenic monoclonal cryocrystalglobulins 128
Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. 127
AL amyloidosis. Characterization of amyloidogenic cells by anti-idiotypic monoclonal antibodies 127
Characterization of the two unique human anti-flavin monoclonal immunoglobulins. 127
Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy 127
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 126
A partially structured species of beta 2-microglobulin is significantly populated under physiological conditions and involved in fibrillogenesis 126
A patient with AL amyloidosis with negative free light chain results 125
Reasoning with Effects of Clinical Guideline Actions Using OWL: AL Amyloidosis as a Case StudyKnowledge Representation for Health-Care 125
Structural characterization of kappa II Inc, a new amyloid immunoglobulin 124
Amino acid sequence of k Sci, the Bence Jones protein isolated from a patient with light chain deposition disease. 124
Bevacizumab treatment followed by maintenance in life-threatening POEMS syndrome. 124
Nutritional counseling improves quality of life and preserves body weight in systemic immunoglobulin light-chain (AL) amyloidosis 124
Cardiac light chain amyloidosis: The role of metal ions in oxidative stress and mitochondrial damage 124
Acute phase proteins and prognosis in multiple myeloma. 124
Obstructive intramural coronary amyloidosis: a distinct phenotype of cardiac amyloidosis that can cause acute heart failure. 123
A novel approach for the purification and proteomic analysis of pathogenic immunglobulin free light chains from serum 123
Amyloid Diseases at the Molecular Level: General Overview and Focus on AL Amyloidosis 123
4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. 122
International prognostic scoring system for Waldenstrom macroglobulinemia 122
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients 122
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 122
Abnormalities in thrombin-antithrombin pathway in AL amyloidosis. 122
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 122
AMYLOIDOSIS AL 121
“Separation and quantification of two beta2-microglobulin isoforms”. 121
ATR-FTIR spectroscopy supported by multivariate analysis for the characterization of adipose tissue aspirates from patients affected by systemic amyloidosis 121
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 121
Autologous stem cell transplantation following heart transplantation for AL amyloidosis 120
Clotting alterations in primary systemic amyloidosis. 119
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 119
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis 119
A Caenorhabditis elegans-based assay recognizes immunoglobulin light chains causing heart amyloidosis 119
Nutritional status evaluation of patients affected by al amyloidosis: a pilot study 118
Bone marrow amyloidosis. 118
Metodo per la separazione e la quantificazione di due conformazioni di beta-2-microglobulina in equilibrio dinamico 118
Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients 118
Clinical, radiological, and biochemical features of a bilateral buttock amyloidoma emerging after 27 years of hemodialysis. 118
Analysis of Vlambda-Jlambda expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambda III) as a new amyloid-associated germline gene segment 118
Use of anti-(beta2 microglobulin) mAb to study formation of amyloid fibrils 117
Waldenstrom macroglobulinemia 117
Hereditary amyloidosis 117
4'-Iodo-4'-deoxydoxorubicin disrupts the fibrillar structure of transthyretin amyloid 117
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 116
Effects of the Known Pathogenic Mutations on the Aggregation Pathway of the Amyloidogenic Peptide of Apolipoprotein A-I. 116
A practical approach to the diagnosis of systemic amyloidoses 116
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. 115
A plea to overcome th concept of "staging" and related inadequacy in multiple myeloma. 114
Biochemical markers in early diagnosis and management of systemic amyloidoses 114
A prospective, controlled, non-randomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple myeloma. 113
Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide 113
Holter monitoring in AL amyloidosis: prognostic implications. 113
Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial 113
Pharmacokinetic behavior of Rituximab: a study of different schedules of administration for heterogeneous clinical settings. 112
Identification of Amyloidogenic Light Chains Requires the Combination of Serum-Free Light Chain Assay with Immunofixation of Serum and Urine 112
Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: Avoiding misdiagnosis of a treatable hereditary neuropathy 112
Characterization of the new serum protein reference material ERM-DA470k/IFCC: value assignment by immunoassay. 111
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 110
Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. 110
Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis 110
Investigating heart-specific toxicity of amyloidogenic immunoglobulin light chains: A lesson from C. elegans 110
Thalidomide plus intermediate-dose dexametasone is an effective but toxic treatment for patients with AL (primary) amyloydosis 110
Prognostication of survival and progression to dialysis in AA amyloidosis 109
Dieta a contenuto controllato di proteine in pazienti affetti da amiloidosi AL con coinvolgimento renale 108
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib and thalidomide 108
Valore prognostico della presenza di disturbi della conduzione cardiaca nei pazienti affetti da amiloidosi AL 108
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis 108
Correlation between serum concentrations of N-terminal natriuretic peptide type B (NT-proBNP) and troponin-I (TnI) in AL amyloidosis 108
Diagnostic performance of triggering receptor expressed on myeloid cells-1 and CD64 index as markers of sepsis in preterm newborns 108
In situ characterization of protein aggregates in human tissues affected by light chain amyloidosis: a FTIR microspectroscopy study 108
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 108
Utility of biochemicalmarkers in the follow-up of heart transplant recipients 107
Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy. 107
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 107
Totale 12.354
Salva come PNG Salva come JPEG
Categoria #
all - tutte 201.102
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 201.102
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202162 0 0 0 0 0 0 0 0 0 0 0 62
2021/20222.073 28 13 56 25 42 59 34 143 128 72 317 1.156
2022/20236.981 815 460 81 552 667 735 22 375 2.973 38 156 107
2023/20242.324 289 458 101 200 259 538 41 145 21 63 121 88
2024/20256.414 135 574 179 216 112 323 231 398 1.636 231 757 1.622
2025/202616.344 1.203 1.186 1.714 1.880 2.070 727 3.162 684 1.478 1.173 588 479
Totale 44.544